NBRVF — Nabriva Therapeutics Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: Nabriva Therapeutics Expands Xenleta(Lefamulin) Presence With Exclusive Agreement With Er-Kim Pharmaceuticals
Brief: Nabriva Therapeutics Reports First Quarter 2022 Financial Results
Nabriva Therapeutics PLC reports results for the quarter ended in March - Earnings Summary
U.S. STOCKS ON THE MOVE-Boeing Co, Rambus Inc, Udemy Inc
U.S. STOCKS ON THE MOVE-Kellogg Co, Fastly Inc, CoreCard Corp
U.S. STOCKS ON THE MOVE-Qorvo Inc, Zoetis Inc, Fisker Inc
Brief: Nabriva Extends Exclusive Agreement To Promote And Distribute Sivextro (Tedizolid Phosphate) In The U.S. Through The End Of 2026
U.S. STOCKS ON THE MOVE-eBay Inc, Nikola Corp, Twitter Inc
Nabriva rises on Merck deal extension for skin infection therapy
Nabriva Therapeutics PLC expected to post a loss of 19 cents a share - Earnings Preview
Brief: Nabriva Therapeutics Announces First Patient Enrolled In Phase 1 Trial Of Xenleta In Adult Patients With Cystic Fibrosis
Nabriva Therapeutics PLC reports results for the quarter ended in December - Earnings Summary
Brief: Nabriva Therapeutics Reports Fourth Quarter Revenue Of $9.3 Mln
Nabriva Therapeutics PLC expected to post a loss of 19 cents a share - Earnings Preview
Nabriva Therapeutics PLC expected to post a loss of 19 cents a share - Earnings Preview
Nabriva Therapeutics PLC expected to post a loss of 19 cents a share - Earnings Preview
Brief: Nabriva Therapeutics Provides Business Update And Announces Preliminary Financial Results For The Fourth Quarter Of 2021
Brief: Nabriva Therapeutics On Jan 4,2022 Received Notice From Nasdaq Saying Co Is Not In Compliance With Certain Requirement For Continued Listing
Brief: Lefamulin NDA Filed In Mainland China For Treatment Of Community Acquired Pneumonia